Wound Management Technologies, Inc. To Present At The Aegis Healthcare And Technology Conference In Las Vegas

ADDISON, TX--(Marketwired - September 03, 2014) - Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patented-protected and FDA-cleared collagen product, CellerateRX®, today announced that the Company’s Chief Executive Officer, Robert Lutz, Jr., is scheduled to present at the Aegis Healthcare and Technology Conference on Friday, September 12, 2014 at 8:30AM PT at the Encore at the Wynn Hotel in Las Vegas, Nevada.

Investors who wish to meet with Mr. Lutz for a one-on-one meeting during the conference should contact KCSA Strategic Communications at WoundManagement@kcsa.com or #212-682-6300.

For more information and to register, please visit the conference website: http://www.bit.ly/AegisConference.

About Wound Management Technologies
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its Wound Care Innovations subsidiary’s unique, patented collagen product line, CellerateRX® which is FDA-cleared for all wound types except 3rd degree burns. The wound care products are reimbursable under Medicare Part B and the surgical products are reimbursed as part of a procedural billing. Wound Management has other advanced biotech products in development including a patented resorbable bone hemostat line that is in late stages of development. For more information visit www.wmgtech.com.

Information about Forward-Looking Statements
The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.